NeuroOne(R) Appoints Jason Mills to the Board of Directors

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has announced the appointment of Jason Mills to its Board of Directors, effective December 18, 2025. Mills is a seasoned med-tech executive currently serving as the Executive Vice President of Strategy at Penumbra, Inc., a prominent medical technology company recognized for its innovations in thrombectomy solutions for critical conditions such as ischemic stroke and venous thromboembolism. With over two decades of experience as a med-tech investment analyst, Mills brings extensive knowledge and expertise to NeuroOne’s leadership.

Previously, Mills was the Managing Director and head of the medical technology equity research practice at Canaccord Genuity, where he developed financial models and conducted comprehensive due diligence on numerous public and private entities in the sector. His accolades include being ranked as the #2 Medical Devices analyst in The Wall Street Journal’s 'Best on the Street' Survey in 2011 and earning the #1 spot in the Medical Products segment of Forbes' Best Brokerage Analysts in 2010. Mills holds a BA in Economics from Yale University and a Master’s in Sports Administration from Ohio University.

According to NeuroOne CEO Dave Rosa, Mills’ deep background in med-tech, combined with his investment insights, will be invaluable as the company focuses on advancing its clinical and corporate objectives. Paul Buckman, Chairman of the Board, also noted that Mills will play a significant role in the company’s governance and strategic initiatives, enhancing its mission to improve diagnosis and treatment for neurological disorders.

NeuroOne specializes in developing innovative, minimally invasive solutions for a range of neurological disorders, targeting improvements in patient outcomes and cost efficiencies.

NeuroOne Medical Technologies Corporation's recent appointment of Jason Mills to its Board of Directors represents a strategic move aimed at bolstering its position within the evolving med-tech landscape. Mills brings extensive experience from Penumbra, where he focused on innovative medical technology and operational strategy. His two-decade tenure as a med-tech investment analyst, particularly at Canaccord Genuity, positions him as an invaluable asset for NeuroOne, likely enhancing investor confidence and strategic oversight.

From a market perspective, this appointment could be a pivotal moment for NeuroOne, especially given its focus on addressing neurological disorders through advanced technologies such as high-definition EEG recording and stimulation solutions. Mills' expertise in financial modeling and due diligence will likely provide critical insights into the company’s clinical goals and resource allocation, potentially translating into improved operational efficiencies and clinical outcomes.

Investors should consider the implications of Mills' addition to the board as a sign of the company's commitment to innovation and growth in the med-tech sector. His role is expected to not only strengthen NeuroOne’s corporate governance but also expand its market reach, which is essential in a field as competitive as medical technology. NeuroOne’s initiatives to transform the diagnosis and treatment of neurological disorders appear well-aligned with the increasing demand for minimally invasive procedures, promising robust market opportunities.

In conclusion, NeuroOne represents a compelling opportunity for investors seeking exposure to a med-tech firm on the cutting edge of treating neurological disorders. With Mills' strategic guidance, combined with the company's innovative approaches, NeuroOne is poised for growth, making it a stock to watch in the coming quarters. Stakeholders should keep a close eye on the execution of their clinical and corporate strategies as they navigate this dynamic landscape.